Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier

Journal of Clinical Pathology

Volumn 67, Issue 7, 2014, Pages 592-598

  Knösel, Thomas ^a   Altendorf Hofmann, Annelore ^b   Lindner, Lars ^c   Issels, Rolf ^c   Hermeking, Heiko ^a   Schuebbe, Gesa ^c   Gibis, Sebastian ^c   Siemens, Helge ^a   Kampmann, Eric ^c   Kirchner, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ANGIOSARCOMA; ARTICLE; BONE TUMOR; CANCER SURVIVAL; DEMETHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SARCOMA; SARCOMA CELL LINE; SENESCENCE; SOFT TISSUE TUMOR; SYNOVIAL SARCOMA; TISSUE MICROARRAY;

MOLECULAR PATHOLOGY; SOFT TISSUE TUMOURS; TUMOUR BIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CELL AGING; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; RNA, MESSENGER; SARCOMA; SOFT TISSUE NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84904358275     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-202106     Document Type: Article

References (16)

1. Fletcher CDM, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press, 2013:468.
2. Sorbye SW, Kilvaer TK, Valkov A, et al. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PloS one 2012;7:e47068.
3. Knosel T, Heretsch S, Altendorf-Hofmann A, et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer 2010;46:1170-6.
4. Bennecke M, Kriegl L, Bajbouj M, et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer cell 2010;18:135-46.
5. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-33. (Pubitemid 47081143)
6. Kriegl L, Neumann J, Vieth M, et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011;24:1015 -22.
7. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379-84.
8. Gutierrez-Reyes G, del Carmen Garcia de Leon M, Varela-Fascinetto G, et al. Cellular senescence in livers from children with end stage liver disease. PloS one 2010;5:e10231.
9. Jeong J, Park YN, Park JS, et al. Clinical signifi cance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J 2005;46:519 -25.
10. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, et al. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 2004;24:349-55.
11. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010;11:561-70.
12. Knosel T, Emde A, Schluns K, et al. Immunopro files of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 2005;7:741-7.
13. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4. (Pubitemid 41117276)
14. Gonzalez RS, McClain CM, Chamberlain BK, et al. Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma. Histopathology 2013;62:1109-11.
15. Thway K, Flora R, Shah C, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol 2012;36:462-9.
16. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31:2024-8.